UBX-1325

Chardan Capital initiates a Buy rating for Unity Biotechnology, citing the potential of UBX1325 in treating diabetic macular edema (DME).

UNITY Biotechnology appointed Federico Grossi as Chief Medical Officer, enhancing its leadership with his extensive experience in ophthalmology and drug development.

Unity Biotechnology's UBX1325, a senolytic therapy, targets diabetic macular edema (DME) by addressing treatment burdens and suboptimal responses.

Unity Biotechnology's Q3 2024 financial results show a reduced net loss of $6.5 million, compared to $14.8 million in Q3 2023, driven by strategic restructuring.

UNITY Biotechnology's UBX1325 (foselutoclax) targets senescent cells in diabetic macular edema (DME), offering a novel approach to address limitations of current anti-VEGF therapies.